1. |
|
|
2. |
- Abbadessa, G, et al.
(author)
-
Unsung hero Robert C. Gallo
- 2009
-
In: Science (New York, N.Y.). - : American Association for the Advancement of Science (AAAS). - 1095-9203 .- 0036-8075. ; 323:5911, s. 206-207
-
Journal article (other academic/artistic)
|
|
3. |
- Bekele, Y, et al.
(author)
-
Undetectable Anti-HBs Antibodies: Need of a Booster Dose for HIV-1-Infected Individuals
- 2021
-
In: Vaccines. - : MDPI AG. - 2076-393X. ; 9:12
-
Journal article (peer-reviewed)abstract
- HBV vaccination effectively prevents HBV transmission and the development of liver cancer. Disease progression and liver-related complications are more common in HIV-1/HBV co-infected than HBV mono-infected individuals. A considerable body of literature, which will be reviewed here, indicates that response to HBV vaccine is suboptimal in HIV-1-infected individuals and that the poor maintenance of protective immunity to HBV vaccines in these individuals is an important medical issue. Several factors affect HBV vaccine response during HIV-1 infection including CD4+ T cell counts, B cell response, vaccine formulation, schedules, and timing of antiretroviral therapy (ART). The initial response to HBV vaccination also plays a critical role in the sustainability of antibody responses in both HIV-1-infected and uninfected vaccinees. Thus, regular follow-up for antibody titer and a booster dose is warranted to prevent HBV transmission in HIV-1 infected people.
|
|
4. |
- Feyissa, YB, et al.
(author)
-
The Role of CXCL13 in Antibody Responses to HIV-1 Infection and Vaccination
- 2021
-
In: Frontiers in immunology. - : Frontiers Media SA. - 1664-3224. ; 12, s. 638872-
-
Journal article (peer-reviewed)abstract
- CXCL13 signals through the G protein-coupled chemokine receptor CXCR5 to drive development of secondary lymphoid tissue as well as B cell and Tfh cell trafficking to germinal centers (GC), which leads to the differentiation of B cells to plasma cells and memory B cells. CXCL13 has been proposed as a general plasma biomarker for GC activities. In HIV-1 infected individuals, plasma CXCL13 levels have been associated with the rate of disease progression to AIDS. Moreover, CXCL13 production has been reported to be increased in HIV-1-infected lymph nodes, which may drive increased downregulation of CXCR5. In this review, we address the role of CXCL13 in HIV-1 infected individuals with regard to GC formation, generation of broadly neutralizing antibodies after infection and vaccination, and AIDS-related B cell lymphoma.
|
|
5. |
|
|